Cellectar Biosciences Announces Presentations at 2014 American Society of Clinical Oncology (ASCO) Annual Meeting

May 30, 2014

Cellectar Biosciences Appoints Chad J. Kolean Chief Financial Officer

May 29, 2014

Cellectar Biosciences Reports First Quarter 2014 Financial Results and Recent Highlights

May 14, 2014

Cellectar Biosciences to Host Conference Call on May 14th to Discuss First Quarter 2014 Results and Provide Quarterly Update on Development Progress

May 12, 2014

Cellectar Biosciences Announces Receipt of Orphan Designation of I-124-CLR1404 as Diagnostic for the Management of Glioma from U.S. Food and Drug Administration

May 5, 2014

Dr. Simon Pedder Becomes President and Chief Executive Officer of Cellectar Biosciences

Apr 2, 2014

Cellectar Biosciences Full-Year 2013 Financial Results and Recent Highlights

Mar 25, 2014

Cellectar Biosciences to Host Conference Call on March 25th to Discuss Full Year 2013 Financial Results and Provide Quarterly Update on Development Progress

Mar 19, 2014

Cellectar Announces Initiation of Phase II Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma

Mar 4, 2014

CORRECTING and REPLACING -- Novelos Therapeutics Announces Corporate Name Change to Cellectar Biosciences, Inc.

Feb 11, 2014